De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Geron Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat Geron de winst en omzet met respectievelijk 68% en 51.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 68.5% per jaar.

Belangrijke informatie

68.0%

Groei van de winst

68.5%

Groei van de winst per aandeel

Biotechs winstgroei	28.7%
Inkomstengroei	51.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	02 Oct 2024

Recente toekomstige groei-updates

Recent updates

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

May 03

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Mar 15

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Mar 05

Is Geron (NASDAQ:GERN) A Risky Investment?

Aug 25

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

May 12

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Dec 20

Geron: A Major Catalyst For Shareholders Arrives In January - At Last

Sep 16

Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?

Sep 14

Geron rises on narrower-than-expected Q2 loss

Aug 12

Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Aug 05

Geron: Waiting For Godot

Jul 15

Geron: TLR Is 10 Months Away

May 03

Winst- en omzetgroeiprognoses

NasdaqGS:GERN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	538	117	-127	N/A	6
12/31/2025	278	-77	-238	N/A	7
12/31/2024	59	-218	-238	N/A	7
6/30/2024	1	-220	-209	-208	N/A
3/31/2024	1	-201	-185	-184	N/A
12/31/2023	0	-184	-169	-168	N/A
9/30/2023	0	-175	-163	-162	N/A
6/30/2023	0	-171	-142	-141	N/A
3/31/2023	0	-150	-141	-140	N/A
12/31/2022	1	-142	-128	-127	N/A
9/30/2022	2	-131	-115	-114	N/A
6/30/2022	1	-117	-108	-108	N/A
3/31/2022	1	-118	-97	-97	N/A
12/31/2021	1	-116	-96	-96	N/A
9/30/2021	0	-108	-86	-86	N/A
6/30/2021	0	-101	-79	-79	N/A
3/31/2021	0	-87	-73	-73	N/A
12/31/2020	0	-76	-67	-67	N/A
9/30/2020	0	-81	-65	-64	N/A
6/30/2020	0	-76	-62	-61	N/A
3/31/2020	0	-75	-58	-57	N/A
12/31/2019	0	-69	-44	-44	N/A
9/30/2019	1	-47	-37	-36	N/A
6/30/2019	1	-37	-31	-31	N/A
3/31/2019	1	-30	-26	-26	N/A
12/31/2018	1	-27	-21	-21	N/A
9/30/2018	1	-27	-22	-22	N/A
6/30/2018	1	-28	-21	-21	N/A
3/31/2018	1	-28	N/A	-21	N/A
12/31/2017	1	-28	N/A	-21	N/A
9/30/2017	1	-29	N/A	-17	N/A
6/30/2017	6	-26	N/A	-19	N/A
3/31/2017	6	-28	N/A	-20	N/A
12/31/2016	6	-30	N/A	-18	N/A
9/30/2016	6	-30	N/A	-23	N/A
6/30/2016	37	1	N/A	-21	N/A
3/31/2016	37	1	N/A	-22	N/A
12/31/2015	36	0	N/A	-24	N/A
9/30/2015	36	0	N/A	10	N/A
6/30/2015	1	-37	N/A	10	N/A
3/31/2015	1	-37	N/A	11	N/A
12/31/2014	1	-36	N/A	9	N/A
9/30/2014	1	-36	N/A	-26	N/A
6/30/2014	1	-35	N/A	-27	N/A
3/31/2014	1	-35	N/A	-30	N/A
12/31/2013	1	-38	N/A	-37	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat GERN de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.5% ).

Winst versus markt: Er wordt verwacht dat GERN de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat GERN binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van GERN ( 51.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van GERN ( 51.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van GERN naar verwachting over 3 jaar hoog zal zijn

Geron Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 16%

Price target increased by 7.0% to US$5.08

Consensus revenue estimates decrease by 13%

Consensus revenue estimates decrease by 21%, EPS upgraded

Forecast to breakeven in 2026

Consensus revenue estimates increase by 76%

Recent updates

Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition

Geron Corporation Announces Chief Commercial Officer to Depart, Effective August 31, 2024

Geron Corporation to Report Q2, 2024 Results on Aug 08, 2024

Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?

Executive VP & COO notifies of intention to sell stock

Chairman of the Board notifies of intention to sell stock

Geron: Innovative Rytelo Enters A Challenging MDS Market

Geron Corporation Announces FDA Approval of RYTELO (imetelstat) for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q1, 2024 Results on May 02, 2024

Consensus revenue estimates decrease by 16%

Geron Corporation, Annual General Meeting, May 09, 2024

Geron Corporation has completed a Follow-on Equity Offering in the amount of $149.999995 million.

Price target increased by 7.0% to US$5.08

Consensus revenue estimates decrease by 13%

New major risk - Share price stability

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Geron Corporation Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Consensus revenue estimates decrease by 21%, EPS upgraded

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q4, 2023 Results on Feb 28, 2024

New minor risk - Share price stability

Forecast to breakeven in 2026

Geron Announces 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Consensus revenue estimates increase by 76%

Geron Corporation has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q3, 2023 Results on Nov 02, 2023

Geron Corporation Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Is Geron (NASDAQ:GERN) A Risky Investment?

Geron Corporation Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

Consensus revenue estimates fall by 14%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Geron Corporation to Report Q2, 2023 Results on Aug 03, 2023

Geron Corporation Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

Geron Corporation Announces Submission of New Drug Application to FDA for First-In-Class Telomerase Inhibitor Imetelstat

Geron Corporation Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

Geron Corporation Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Consensus revenue estimates increase by 29%

Geron Corporation Announces Board Changes

Consensus revenue estimates decrease by 48%, EPS upgraded

Geron Corporation Announces Five Abstracts Related to Imetelstat Accepts at European Hematology Association Annual Meeting

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Chairman of the Board notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

Price target increased to US$4.50

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Geron Corporation Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Geron Corporation to Report Q3, 2022 Results on Nov 03, 2022

Executive VP & COO exercised options to buy US$634k worth of stock.

Geron: A Major Catalyst For Shareholders Arrives In January - At Last

Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?

Geron Corporation Appoints John F. McDonald to Board of Directors

Geron Corporation Announces Update on Securities Class Action Lawsuit